In early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.
Dutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQure’s Audit Committee.
RS Genomics, formed to provide broad access to CRISPR/Cas9 IP, has appointed Eric Rhodes as its new CEO. He joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.
In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France’s Servier.
When Sanofi sells its animal health division Merial, CEO Carsten Hellmann will join Danish allergy specialist ALK Albello as the next President and CEO. He will also give up his seat on the Executive Committee and his position of Executive Vice President at Sanofi.
British research service provider Envigo has appointed Scott Schulz to the post of Director, North American Operations. Schulz joins Envigo from Taconic Biosciences, where he was VP of Operations.
Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.
Swedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.
Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.
Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genae’s research services.